2005
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. JAMA Psychiatry 2005, 62: 961-970. PMID: 16143728, DOI: 10.1001/archpsyc.62.9.961.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsBrief Psychiatric Rating ScaleDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePlacebosPsychotic DisordersRandomized Controlled Trials as TopicResearch DesignSchizophreniaSchizophrenic PsychologySelection BiasSeverity of Illness IndexSex FactorsTreatment OutcomeConceptsBrief Psychiatric Rating ScalePlacebo-controlled trialPsychiatric Rating ScalePlacebo-controlled studyAtypical antipsychotic medicationsDose-controlled studyMedication trialsAntipsychotic medicationRating ScaleDouble-blind clinical trialNew atypical antipsychotic medicationsDose-controlled trialsTreatment completion ratesPlacebo control groupEnd point changePercentage of menDrug Administration databaseRandom effects analysisIll adultsMedication armClinical trialsNew medicationsNovel medicationsSame drugAverage age
1988
Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases
Makuch R, Rosenberg P, Mulshine J. Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases. Statistics In Medicine 1988, 7: 843-856. PMID: 2842852, DOI: 10.1002/sim.4780070803.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesFunction testsOutcome dataSmall cell lung cancerImportant prognostic variablesCell lung cancerLogistic regression modelsPrognostic factorsLung cancerPrognostic variablesMetastasisBinary outcome dataSpecific guidelinesRegression modelsAgeStandard logistic regression model
1987
Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.
Schechter G, Sausville E, Fischmann A, Soehnlen F, Eddy J, Matthews M, Gazdar A, Guccion J, Munson D, Makuch R. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987, 69: 841-9. PMID: 3493044, DOI: 10.1182/blood.v69.3.841.bloodjournal693841.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaBlood involvementLymphocyte morphologyRisk factorsCell lymphomaCTCL cellsIndependent risk factorExtent of diseasePretreatment risk factorsPeripheral blood lymphocyte morphologyUntreated patientsVisceral diseaseWorse survivalLymph nodesInitial diagnosisT stageAggressive featuresSkin stageCutaneous tumorsSkin plaquesPrognostic informationPatientsMalignant cellsMultivariate analysis
1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1980
Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma
Glaubiger D, Makuch R, Schwarz J, Levine A, Johnson R. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45: 2213-2219. PMID: 7370962, DOI: 10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrognostic factorsEwing's sarcomaTreatment groupsLactic acid dehydrogenasePrimary diseaseSerum lactic acid dehydrogenaseSystemic chemotherapy regimensFavorable prognostic factorTime of presentationLactic acid dehydrogenase levelsNumber of patientsResults of treatmentNational Cancer InstituteLatest regimensChemotherapy regimensMetastatic diseaseFavorable prognosisMetastatic statusFavorable outcomeTherapeutic resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer Institute
1979
Justification for the lognormal distribution as a model for blood pressure
Makuch R, Freeman D, Johnson M. Justification for the lognormal distribution as a model for blood pressure. Journal Of Clinical Epidemiology 1979, 32: 245-250. PMID: 429469, DOI: 10.1016/0021-9681(79)90070-5.Peer-Reviewed Original Research